Do analysts rate ADXN or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ADXN or BPTH more profitable?

Addex Therapeutics' return on equity of -134.76% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -134.76% -106.00% Bio-Path N/A -2,842.40% -337.48%

Do analysts recommend PCSA or BPTH?

Heatwurx presently has a consensus price target of $25.00, suggesting a potential upside of 928.81%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts plainly believe Heatwurx is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, PCSA or BPTH?

Heatwurx is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$9.29 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is PCSA or BPTH more profitable?

Heatwurx's return on equity of -281.31% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Bio-Path N/A -2,842.40% -337.48%

Do analysts recommend BPTH or ACXP?

Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 2,122.22%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, BPTH or ACXP?

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A

Is BPTH or ACXP more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Acurx Pharmaceuticals N/A -153.92% -101.69%

Do analysts prefer CVKD or BPTH?

Cadrenal Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 595.19%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Cadrenal Therapeutics is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, CVKD or BPTH?

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is CVKD or BPTH more profitable?

Cadrenal Therapeutics' return on equity of -411.03% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -411.03% -275.61% Bio-Path N/A -2,842.40% -337.48%

Do analysts rate SNOA or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Bio-Path (BPTH) Competitors

$0.04 +0.01 (+16.00%)

As of 03:13 PM Eastern

Compare

BPTH vs. ADXN, PCSA, ACXP, CVKD, and SNOA

Should you buy Bio-Path stock or one of its competitors? Bio-Path's main competitors and comparable companies include Addex Therapeutics (ADXN), Heatwurx (PCSA), Acurx Pharmaceuticals (ACXP), Cadrenal Therapeutics (CVKD), and Sonoma Pharmaceuticals (SNOA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bio-Path compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Addex Therapeutics has higher revenue and earnings than Bio-Path. Addex Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	32.13	-$8.12M	-$5.94	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Addex Therapeutics' return on equity of -134.76% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
Bio-Path	N/A	-2,842.40%	-337.48%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Addex Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, suggesting that its stock price is 151% less volatile than the broader market.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Addex Therapeutics had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for Addex Therapeutics and 0 mentions for Bio-Path. Addex Therapeutics' average media sentiment score of 0.44 beat Bio-Path's score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Addex Therapeutics	Neutral
Bio-Path	Neutral

Summary

Addex Therapeutics beats Bio-Path on 10 of the 12 factors compared between the two stocks.

How does Bio-Path compare to Heatwurx?

Heatwurx (NASDAQ:PCSA) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Heatwurx's return on equity of -281.31% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Bio-Path	N/A	-2,842.40%	-337.48%

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 3.5% of Heatwurx shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Heatwurx presently has a consensus price target of $25.00, suggesting a potential upside of 928.81%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts plainly believe Heatwurx is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Heatwurx had 3 more articles in the media than Bio-Path. MarketBeat recorded 3 mentions for Heatwurx and 0 mentions for Bio-Path. Heatwurx's average media sentiment score of 0.44 beat Bio-Path's score of 0.00 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Neutral
Bio-Path	Neutral

Heatwurx is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Heatwurx has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, meaning that its share price is 151% less volatile than the broader market.

Summary

Heatwurx beats Bio-Path on 11 of the 13 factors compared between the two stocks.

How does Bio-Path compare to Acurx Pharmaceuticals?

Bio-Path (NASDAQ:BPTH) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 2,122.22%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bio-Path has a beta of -0.51, meaning that its share price is 151% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.03, meaning that its share price is 303% less volatile than the broader market.

Acurx Pharmaceuticals' return on equity of -153.92% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Acurx Pharmaceuticals had 6 more articles in the media than Bio-Path. MarketBeat recorded 6 mentions for Acurx Pharmaceuticals and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 beat Acurx Pharmaceuticals' score of -0.23 indicating that Bio-Path is being referred to more favorably in the media.

Company	Overall Sentiment
Bio-Path	Neutral
Acurx Pharmaceuticals	Neutral

Summary

Acurx Pharmaceuticals beats Bio-Path on 9 of the 13 factors compared between the two stocks.

How does Bio-Path compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Cadrenal Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, suggesting that its share price is 151% less volatile than the broader market.

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 14.6% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cadrenal Therapeutics' return on equity of -411.03% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Bio-Path	N/A	-2,842.40%	-337.48%

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Cadrenal Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 595.19%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Cadrenal Therapeutics is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Bio-Path. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 0 mentions for Bio-Path. Cadrenal Therapeutics' average media sentiment score of 1.09 beat Bio-Path's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Bio-Path	Neutral

Summary

Cadrenal Therapeutics beats Bio-Path on 11 of the 13 factors compared between the two stocks.

How does Bio-Path compare to Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Sonoma Pharmaceuticals has higher revenue and earnings than Bio-Path. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$21.92M	0.28	-$3.17M	-$1.22	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Bio-Path has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -26.32% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-26.32%	-6.55%
Bio-Path	N/A	-2,842.40%	-337.48%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sonoma Pharmaceuticals had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 0 mentions for Bio-Path. Sonoma Pharmaceuticals' average media sentiment score of 1.44 beat Bio-Path's score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Positive
Bio-Path	Neutral

Sonoma Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, suggesting that its stock price is 151% less volatile than the broader market.

Summary

Sonoma Pharmaceuticals beats Bio-Path on 9 of the 13 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTH vs. The Competition

Export

Metric	Bio-Path	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.08M	$11.73B	$6.98B	$13.04B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-0.04	781.47	269.86	25.30
Price / Sales	N/A	750.79	601.81	101.06
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	0.06	10.81	13.08	6.33
Net Income	-$16.08M	$2.77B	$3.45B	$347.70M
7 Day Performance	N/A	0.17%	1.12%	1.07%
1 Month Performance	N/A	0.35%	1.79%	1.03%
1 Year Performance	N/A	161.52%	67.69%	20.77%

Bio-Path Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTH Bio-Path	N/A	$0.04 +16.0%	N/A	-75.0%	$2.08M	N/A	N/A	10	Upcoming Earnings Gap Up
ADXN Addex Therapeutics	0.258 of 5 stars	$5.72 -3.9%	N/A	-29.4%	$7.05M	$29.97K	N/A	30	Short Interest Increase
PCSA Heatwurx	3.0075 of 5 stars	$2.51 -4.6%	$25.00 +896.0%	-56.1%	$6.95M	N/A	N/A	20	Earnings Report Short Interest Increase
ACXP Acurx Pharmaceuticals	2.4643 of 5 stars	$1.54 +4.8%	$31.00 +1,913.0%	-68.6%	$6.62M	N/A	N/A	3	News Coverage Earnings Report Gap Up
CVKD Cadrenal Therapeutics	2.4767 of 5 stars	$1.89 -2.6%	$13.00 +587.8%	-84.1%	$6.46M	N/A	N/A	4	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Path (BPTH) Competitors

BPTH vs. ADXN, PCSA, ACXP, CVKD, and SNOA

How does Bio-Path compare to Addex Therapeutics?

Summary

How does Bio-Path compare to Heatwurx?

Summary

How does Bio-Path compare to Acurx Pharmaceuticals?

Summary

How does Bio-Path compare to Cadrenal Therapeutics?

Summary

How does Bio-Path compare to Sonoma Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Path (BPTH) Competitors

BPTH vs. ADXN, PCSA, ACXP, CVKD, and SNOA

How does Bio-Path compare to Addex Therapeutics?

Which has better earnings & valuation, ADXN or BPTH?

Is ADXN or BPTH more profitable?

Do analysts rate ADXN or BPTH?

Which has more risk and volatility, ADXN or BPTH?

Do institutionals and insiders have more ownership in ADXN or BPTH?

Does the media refer more to ADXN or BPTH?

Summary

How does Bio-Path compare to Heatwurx?

Is PCSA or BPTH more profitable?

Do insiders and institutionals have more ownership in PCSA or BPTH?

Do analysts recommend PCSA or BPTH?

Does the media favor PCSA or BPTH?

Which has better valuation and earnings, PCSA or BPTH?

Which has more volatility & risk, PCSA or BPTH?

Summary

How does Bio-Path compare to Acurx Pharmaceuticals?

Do analysts recommend BPTH or ACXP?

Which has more risk and volatility, BPTH or ACXP?

Is BPTH or ACXP more profitable?

Which has stronger earnings and valuation, BPTH or ACXP?

Do institutionals & insiders believe in BPTH or ACXP?

Does the media prefer BPTH or ACXP?

Summary

How does Bio-Path compare to Cadrenal Therapeutics?

Which has more risk and volatility, CVKD or BPTH?

Do insiders & institutionals have more ownership in CVKD or BPTH?

Is CVKD or BPTH more profitable?

Which has higher valuation & earnings, CVKD or BPTH?

Do analysts prefer CVKD or BPTH?

Does the media favor CVKD or BPTH?

Summary

How does Bio-Path compare to Sonoma Pharmaceuticals?

Which has stronger earnings and valuation, SNOA or BPTH?

Is SNOA or BPTH more profitable?

Do analysts rate SNOA or BPTH?

Do insiders and institutionals have more ownership in SNOA or BPTH?

Does the media refer more to SNOA or BPTH?

Which has more volatility and risk, SNOA or BPTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools